# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Bio-Path shares ended Wednesday's session slightly higher after the company provided an update from its ongoing Phase 1/1b ...
Bio-Path Holdings (NASDAQ:BPTH) reported quarterly losses of $(1.16) per share which beat the analyst consensus estimate of $(1...
Roth MKM analyst Philip Shen reiterates Bio-Path Hldgs (NASDAQ:BPTH) with a Buy and maintains $20 price target.
Peter H. Nielsen, President and Chief Executive Officer of Bio-Path, said, "With the increased clinical data that we have g...